LH

Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development, medical device and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.

Wall Street analysts forecast LH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LH is 307.00 USD with a low forecast of 270.00 USD and a high forecast of 342.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Labcorp Holdings Inc revenue for the last quarter amounts to 3.56B USD, increased 8.58 % YoY.

Labcorp Holdings Inc. EPS for the last quarter amounts to 3.12 USD, increased 55.22 % YoY.

Labcorp Holdings Inc (LH) has 70000 emplpoyees as of December 16 2025.

Today LH has the market capitalization of 21.83B USD.